» Articles » PMID: 16886979

Inactivation of Caspase-1 in Rodent Brain: a Novel Anticonvulsive Strategy

Overview
Journal Epilepsia
Specialty Neurology
Date 2006 Aug 5
PMID 16886979
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Cytokines and related inflammatory mediators are rapidly synthesized in the brain during seizures. We previously found that intracerebral administration of interleukin-1 (IL-1)-beta has proconvulsant effects, whereas its endogenous receptor antagonist (IL-1Ra) mediates potent anticonvulsant actions in various models of limbic seizures. In this study, we investigated whether seizures can be effectively inhibited by blocking the brain production of IL-1beta, by using selective inhibitors of interleukin-converting enzyme (ICE/caspase-1) or through caspase-1 gene deletion.

Methods: Caspase-1 was selectively blocked by using pralnacasan or VX-765. IL-1beta release was induced in mouse organotypic hippocampal slice cultures by proinflammatory stimuli [lipopolysaccharide (LPS) + adenosine triphosphate (ATP)] and measured with enzyme-linked immunosorbent assay (ELISA). IL-1beta production during seizures was measured in the rat hippocampus by Western blot. Seizures were induced in freely moving mice and rats by intrahippocampal injection of kainic acid and recorded by EEG analysis.

Results: Caspase-1 inhibition reduced the release of IL-1beta in organotypic slices exposed to LPS+ATP. Administration of pralnacasan (intracerebroventricular, 50 microg) or VX-765 (intraperitoneal, 25-200 mg/kg) to rats blocked seizure-induced production of IL-1beta in the hippocampus, and resulted in a twofold delay in seizure onset and 50% reduction in seizure duration. Mice with caspase-1 gene deletion showed a 70% reduction in seizures and an approximate fourfold delay in their onset.

Conclusions: Inhibition of caspase-1 represents an effective and novel anticonvulsive strategy, which acts by selectively reducing the brain availability of IL-1beta.

Citing Articles

The concealed side of caspases: beyond a killer of cells.

Abdelghany L, Sillapachaiyaporn C, Zhivotovsky B Cell Mol Life Sci. 2024; 81(1):474.

PMID: 39625520 PMC: 11615176. DOI: 10.1007/s00018-024-05495-7.


Inflammasomes at the crossroads of traumatic brain injury and post-traumatic epilepsy.

Javalgekar M, Jupp B, Vivash L, OBrien T, Wright D, Jones N J Neuroinflammation. 2024; 21(1):172.

PMID: 39014496 PMC: 11250980. DOI: 10.1186/s12974-024-03167-8.


Advances in understanding the pathogenesis of epilepsy: Unraveling the molecular mechanisms: A cross-sectional study.

Shariff S, Nouh H, Inshutiyimana S, Kachouh C, Abdelwahab M, Nazir A Health Sci Rep. 2024; 7(2):e1896.

PMID: 38361811 PMC: 10867297. DOI: 10.1002/hsr2.1896.


Pathophysiology to Risk Factor and Therapeutics to Treatment Strategies on Epilepsy.

de Araujo Boleti A, Cardoso P, Frihling B, de Moraes L, Nunes E, Mukoyama L Brain Sci. 2024; 14(1).

PMID: 38248286 PMC: 10813806. DOI: 10.3390/brainsci14010071.


Neuroinflammation and status epilepticus: a narrative review unraveling a complex interplay.

Foiadelli T, Santangelo A, Costagliola G, Costa E, Scacciati M, Riva A Front Pediatr. 2023; 11:1251914.

PMID: 38078329 PMC: 10703175. DOI: 10.3389/fped.2023.1251914.